FDMT

4.31

3.86% 0.16

Dopo l'orario di chiusura: 4.31

4 D Molecular Therapeutics Inc (FDMT)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$4.15

Aprire:

$4.15

Volume 24 ore:

619.36K

Relative Volume:

1.08

Capitalizzazione di mercato:

$207.07M

Reddito:

$20.72M

Utile/perdita netta:

$-100.84M

Rapporto P/E:

-1.6203

EPS:

-2.66

Flusso di cassa netto:

$-78.56M

1 W Prestazione:

+5.64%

1M Prestazione:

+14.93%

6M Prestazione:

-26.07%

1 anno Prestazione:

-79.06%

Intervallo 1D:

$4.15

$4.40

Intervallo di 1 settimana:

$3.68

$4.40

Portata 52W:

$2.235

$28.93

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Nome

4 D Molecular Therapeutics Inc

Settore

Healthcare (1166)

Industria

Biotechnology (655)

Telefono

(510) 505-2680

Indirizzo

5858 HORTON STREET #455, EMERYVILLE

Dipendente

227

Cinguettio

Prossima data di guadagno

2024-12-13

Ultimi documenti SEC

FDMT's Discussions on Twitter

Confronta FDMT con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
FDMT 4 D Molecular Therapeutics Inc	4.31	207.07M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	457.03	115.95B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	547.74	56.52B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	329.77	39.44B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	545.11	35.14B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	244.32	28.51B	3.81B	-644.79M	-669.77M	-6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-01-13	Downgrade	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Iniziato	Morgan Stanley	Underweight
2024-09-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Iniziato	Barclays	Overweight
2024-02-07	Ripresa	Goldman	Buy
2023-10-26	Iniziato	RBC Capital Mkts	Outperform
2023-10-24	Iniziato	Cantor Fitzgerald	Overweight
2023-10-18	Aggiornamento	Leerink Partners	Market Perform → Outperform
2023-07-05	Iniziato	Chardan Capital Markets	Buy
2023-01-30	Iniziato	BMO Capital Markets	Outperform
2022-11-18	Iniziato	H.C. Wainwright	Buy
2022-11-15	Aggiornamento	Goldman	Neutral → Buy
2022-08-12	Downgrade	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Iniziato	Jefferies	Buy
2022-01-04	Iniziato	SVB Leerink	Outperform
2021-01-05	Iniziato	BofA Securities	Buy
2021-01-05	Iniziato	Evercore ISI	Outperform
2021-01-05	Iniziato	Goldman	Neutral

Mostra tutto

4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie

Jun 17, 2025

Cystic Fibrosis Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

Jun 17, 2025

Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED

Jun 17, 2025

Jun 16, 2025

Gene Therapy in Ophthalmology Market Set to Transform Vision Restoration Landscape by 2034 | Says DelveInsight - Barchart.com

Jun 16, 2025

Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Jun 16, 2025

Jun 13, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Stock Position Raised by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Jun 13, 2025

Jun 12, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Jun 12, 2025

908 Devices’ (MASS) “Sell (D-)” Rating Reiterated at Weiss Ratings - Defense World

Jun 12, 2025

Organigram (TSE:OGI) Stock Price Up 2% – Should You Buy? - Defense World

Jun 12, 2025

Analysts Issue Forecasts for FDMT FY2026 Earnings - Defense World

Jun 12, 2025

Jun 11, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer - The Manila Times

Jun 11, 2025

Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - GlobeNewswire

Jun 10, 2025

Jun 05, 2025

4D Molecular Therapeutics Being Investigated on Behalf of 4D Molecular Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details - ACCESS Newswire

Jun 05, 2025

Jun 04, 2025